News AZ's bid for Fasenra approval in COPD falls short AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.
News GSK forges $12bn alliance with China's Hengrui GSK has moved to shore up its R&D pipeline with a strategic-level partnering deal with China's Jiangsu Hengrui Pharma.
News Roche's COPD candidate fails a phase 3 readout Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.
News GSK claims first approval for Nucala in COPD GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.
News GSK sets up Nucala and Dupixent showdown in COPD GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.
News Verona says COPD drug is off to a flying start Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.